|
Market Closed -
Euronext Paris
09:25:00 20/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.3830 EUR | -0.26% |
|
-0.91% | +28.52% |
| 10/08 | Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China | CI |
| 10/08 | Nicox Partner Files China Drug Application for NCX 470 Eye Drop | MT |
| Market Cap | 3.38Cr 3.94Cr 3.15Cr 2.89Cr 5.43Cr 377.22Cr 5.54Cr 37Cr 15Cr 189.05Cr 15Cr 14Cr 625.87Cr | P/E 2026 * |
-5.47x | P/E 2027 * | 38.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.38Cr 3.94Cr 3.15Cr 2.89Cr 5.43Cr 377.22Cr 5.54Cr 37Cr 15Cr 189.05Cr 15Cr 14Cr 625.87Cr | EV / Sales 2026 * |
11.3x | EV / Sales 2027 * | 3.38x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.26% | ||
| 1 week | -0.91% | ||
| Current month | -0.91% | ||
| 1 month | +3.51% | ||
| 3 months | -2.54% | ||
| 6 months | -7.71% | ||
| Current year | +28.52% |
| 1 week | 0.38 |  | 0.39 |
| 1 month | 0.37 | | 0.4 |
| Current year | 0.29 | | 0.57 |
| 1 year | 0.28 | | 0.57 |
| 3 years | 0.14 | | 0.65 |
| 5 years | 0.14 | | 3.84 |
| 10 years | 0.14 | | 13.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 29/01/22 | Free | Chief Executive Officer | 15,000 | 0.0348% | ||
| 16/02/21 | Fiscal year | Chief Executive Officer | 10,000 | 0.0270% | ||
| 01/02/20 | Free | Chief Executive Officer | 10,000 | 0.0300% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.26% | -0.91% | -11.75% | -10.20% | 3.94Cr | |
| -2.11% | +9.92% | +75.99% | +36.44% | 37TCr | |
| -0.22% | -1.04% | +23.65% | -13.20% | 7.01TCr | |
| -1.39% | +5.41% | +49.19% | +145.31% | 1.2TCr | |
| -1.98% | -0.27% | -2.20% | -0.41% | 865.73Cr | |
| +1.41% | -1.26% | -10.82% | 0.00% | 486.21Cr | |
| +4.77% | +1.09% | -26.39% | +19.47% | 446.43Cr | |
| +8.85% | -18.65% | -15.25% | +23.50% | 348.42Cr | |
| -2.25% | +0.64% | +11.18% | +53.21% | 275.81Cr | |
| +1.95% | -2.83% | -8.04% | -4.20% | 217.18Cr | |
| Average | +0.90% | -0.58% | +8.55% | +24.99% | 4.76TCr | |
| Weighted average by Cap. | -1.58% | +7.51% | +62.90% | +30.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30L 35.04L 27.99L 25.68L 48.26L 34Cr 49.21L 3.32Cr 1.29Cr 17Cr 1.32Cr 1.29Cr 56Cr | 1Cr 1.17Cr 93.3L 85.61L 1.61Cr 111.75Cr 1.64Cr 11Cr 4.31Cr 56Cr 4.39Cr 4.29Cr 185.42Cr |
| Net income | -60L -70.08L -55.98L -51.37L -96.52L -67Cr -98.42L -6.64Cr -2.59Cr -34Cr -2.63Cr -2.57Cr -111.25Cr | 10L 11.68L 9L 9L 16.09L 11Cr 16.4L 1.11Cr 43.15L 5.6Cr 43.85L 42.9L 19Cr |
| Net Debt | - | - |
Employees
10
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | €0.3830 | -0.26% | 99,045 |
| 19/26/19 | €0.3840 | +0.26% | 1,10,264 |
| 18/26/18 | €0.3830 | -0.78% | 64,858 |
| 17/26/17 | €0.3860 | +0.26% | 82,591 |
| 14/26/14 | €0.3850 | -0.39% | 1,77,114 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3830EUR
Average target price
1.000EUR
Spread / Average Target
+161.10%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALCOX Stock
Select your edition
All financial news and data tailored to specific country editions
